OvaScience Securities Litigation
HomeCase DocumentsFrequently Asked QuestionsContact Us

Welcome to the OvaScience Securities Litigation Website

This website has been established to provide general information related to the OvaScience Securities Litigation.

This is a securities class action alleging violations of the Securities Exchange Act of 1934 brought against OvaScience, Inc. ("OvaScience") and several other individuals and entities. The case is presently pending before the United States District Court for the District of Massachusetts (the “Court”) and is captioned Dahhan v. Ovascience, Inc. Civil Action No. 1:17-cv-10511-IT (the “Litigation”).

Pursuant to orders dated May 8, 2020 and May 18, 2020, the Court certified this securities case as a class action to proceed on behalf of the Class. Lead Plaintiff Freedman Family Investments, LLC has been appointed Class Representative.

 The Class is defined as:

Persons or entities that purchased or otherwise acquired the publicly traded shares of OvaScience common stock between December 17, 2014 and September 28, 2015, inclusive ("Class Period"). Excluded from the Class are Defendants, the officers and directors of OvaScience, at all relevant times, members of their immediate families and their legal representatives, heirs, successors, or assigns, and any entity which Defendants have or had a controlling interest.

By certifying the Class, the Court did not suggest that Plaintiff will win or lose this case. Litigation is ongoing.  No trial date has yet been set.

If you or someone acting on your behalf purchased or otherwise acquired publicly traded shares of OvaScience common stock during the Class Period, you may be a “Class Member” entitled to participate in any benefits that may eventually be obtained for the Class as a result of this Litigation.

Background and Description of the Litigation

The Amended Class Action Complaint (the “Complaint”) alleges that Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by knowingly or recklessly misrepresenting and concealing material facts during the Class Period regarding the efficacy and commercial viability of AUGMENT, which the Complaint alleges was the Company’s only developed treatment. The Complaint alleges that AUGMENT, a new fertility treatment, was intended to improve egg health and address problems in the development of newly formed embryos caused by inadequate energy in the cell division process. The Class Representative seeks, for itself and all other similarly situated persons, compensatory damages, interest, and reasonable costs and expenses, including attorneys’ fees and experts’ fees.

The publishing of this Website and mailing of the Notice is not an expression by the Court of any opinion on the likelihood of recovery by the Class Representative or on the merits of any defense asserted by Defendants. Litigation is ongoing. This Notice is provided only so that you may decide what steps, if any, to take in relation to your continued participation in the Class.

Defendants have denied and continue to deny all claims of wrongdoing or liability against them arising out of any of the conduct, statements, acts, or omissions alleged in the Complaint, including any alleged violations of the federal securities laws or any other legal obligation or duty potentially giving rise to the claims alleged in the Complaint. Defendants have denied and continue to deny each of the claims alleged by the Class Representative on behalf of the Class, including all claims in the Complaint. Defendants believe that they have meritorious defenses to all claims asserted or that could have been asserted based on the allegations of the Complaint. Specifically, Defendants have denied and continue to deny, among other things, that: the alleged misrepresentations or non-disclosures were materially false; the Defendants knowingly or recklessly made false or misleading statements; the Class Representative and the Class have suffered damages; the prices of OvaScience common stock were artificially inflated during the Class Period by reason of the alleged misrepresentations, non-disclosures, or otherwise; and the Class Representative and the Class were otherwise harmed in any other way by the conduct alleged in the Complaint. Moreover, Defendants believe that the evidence developed to date supports their position and assert that the allegations in the Complaint have no merit. Litigation is ongoing. No trial date has yet been set by the Court.

Additional Information

Although the information on this website is intended to assist you, it does not replace the information contained in the Notice of Pendency of Class Action which can be found and downloaded on the Case Documents page of this website. We recommend that you read the Notice and other relevant case documents carefully. You may also wish to read the answers to Frequently Asked Questions provided on this website. If you have not received a notice and would like to confirm that you are on the mailing list for further notice mailings in this matter, please contact the Notice Administrator and request that a notice be sent to you at your current mailing address.

Important Dates and Deadlines

Request Exclusion September 4, 2020